Amylyx Pharmaceuticals Shares Rise 6.9% on Positive News

The biotech company's stock jumps after positive analyst ratings and coverage.

Apr. 6, 2026 at 6:57pm

Got story updates? Submit your updates here. ›

An extreme close-up of the complex, interlocking components of a high-tech medical device, conveying the sophisticated science and engineering driving Amylyx Pharmaceuticals' innovative approach to neurological treatments.The advanced machinery and engineering behind Amylyx Pharmaceuticals' promising neurological drug pipeline.Cambridge Today

Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) rose 6.9% on Monday, trading as high as $16.20 per share. The increase comes after several research analysts issued positive ratings and price targets for the biotech company's stock.

Why it matters

Amylyx Pharmaceuticals is developing treatments for rare and debilitating neurological diseases, an area of significant unmet medical need. The positive analyst sentiment suggests growing confidence in the company's pipeline and commercial prospects.

The details

The stock's rise was driven by increased trading volume, up 15% from the average daily volume. Several analysts, including those from HC Wainwright, Stifel Nicolaus, and Guggenheim, have issued buy ratings and price targets ranging from $21 to $34 per share for Amylyx. The company's lead product, AMX0035, was recently approved by the FDA for the treatment of amyotrophic lateral sclerosis (ALS).

  • Amylyx Pharmaceuticals shares closed at $14.95 on the previous trading day.
  • The stock traded as high as $16.20 on Monday, April 6, 2026.

The players

Amylyx Pharmaceuticals, Inc.

A biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases.

HC Wainwright

An investment bank that has issued a buy rating and $34 price target for Amylyx Pharmaceuticals.

Stifel Nicolaus

An investment bank that has initiated coverage of Amylyx Pharmaceuticals with a buy rating and $21 price target.

Guggenheim

An investment bank that has raised its price target for Amylyx Pharmaceuticals from $25 to $30, maintaining a buy rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

Analysts will continue to monitor Amylyx Pharmaceuticals' progress with its lead drug candidate AMX0035 and the company's broader pipeline as it seeks to address unmet needs in neurological diseases.

The takeaway

The positive analyst sentiment and stock price increase for Amylyx Pharmaceuticals reflect growing optimism around the company's potential to develop effective treatments for rare and debilitating neurological conditions, an area of significant medical need.